Post Type Archives: News

Sanofi announced it has entered into an agreement to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, UK. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. […]

Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, is pleased to announce the appointment of Thomas Rohrer as Vice President of Bioconjugation. This appointment follows a recently announced investment to establish cGMP bioconjugation capabilities at its Devens, MA site. Thomas brings […]

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the appointment of Dr Adam Gilbert to its Scientific Advisory Board. In the role, Adam will support PhoreMost to advance its portfolio of novel small molecule degraders and molecular glues arising from its GlueSEEKER® […]

Sygnature Discovery, a leading integrated drug discovery contract research organisation (CRO), today announces the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment. In today’s demanding drug discovery landscape, accelerating time to value inflection remains a top industry priority. Sygnature’s enhanced high-throughput chemistry (HTC) platform […]

Lonza reported sales of CHF 3.6 billion in H1 2025, reflecting CER sales growth of 19.0% (17.0% AER3). CHF 1.1 billion CORE EBITDA resulted in a robust margin of 29.6% (+0.4ppts versus H1 2024). Including the contribution from the recently acquired Vacaville (US) site, the CDMO business delivered CER sales growth of 23.1% and a […]

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately. Mr. Glass has served as Chairman of the Board since 2022. Mr. Glass brings 30 years of experience in the life sciences industry within both innovators and […]

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities of its high-throughput GlueSEEKER platform to accelerate the design and development of novel molecular glue degraders1. The paper, titled “Systematic molecular glue drug discovery with a […]

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing centre focused on chronic diseases in the Commonwealth of Virginia, the Company’s largest single investment in a facility to date AstraZeneca today announces $50 billion […]

Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US Cornerstone of investment is a proposed new multi-billion dollar drug substance manufacturing centre focused on chronic diseases in the Commonwealth of Virginia, the Company’s largest single investment in a facility to date AstraZeneca announced $50 billion of […]

Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi’s steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture […]